Partial
Mostly Aligned
Patient Risk:
Low
Summary
The AI-generated claims largely align with the labeled indications and key efficacy and administration details. However, multiple claims are either not supported by the label or are stated with inaccuracies (e.g., trial comparisons and regional approval details). Several items are lacking label support altogether. Overall, the alignment is partial.
Category Scores
Accurate Statements
Kesimpta (ofatumumab) is an FDA-approved monoclonal antibody.
Sections 1 and 12.1
Kesimpta is approved for adults with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS.
Section 1
Kesimpta targets CD20 on B cells to reduce their numbers.
Section 12.1
Kesimpta slows disease progression and relapse rates.
Section 14
Kesimpta is administered as a monthly subcutaneous self-injection.
Sections 2.2 and 2.3
In ASCLEPIOS I/II trials, Kesimpta reduced brain lesion activity.
Section 14
Injection reactions occur (up to 21%).
Section 6.1
Upper respiratory infections occur (39%).
Section 5.1
Progressive multifocal leukoencephalopathy (PML) is a listed risk.
Section 5.2
Hepatitis B reactivation is a listed risk.
Section 5.2
Monitoring for infections is required.
Section 5.1
Kesimpta outperforms teriflunomide on relapses.
Section 14
Kesimpta has comparable disability progression data to teriflunomide.
Section 14
Unsupported Statements
Kesimpta effects start within a week.
No label support for onset within one week.
Novartis developed and markets Kesimpta.
Label does not state Novartis as developer/markets Kesimpta.
The FDA approved it in August 2020 for RMS.
Label does not specify approval date.
Kesimpta is approved in Europe and other regions.
Label does not specify European or other regional approvals.
Kesimpta offers at-home subcutaneous dosing with similar B-cell depletion to Ocrevus.
Label does not compare to Ocrevus.
Kesimpta has a potentially faster onset than Ocrevus.
Label does not provide a comparative onset statement with Ocrevus.
Patent/hardware/biologic exclusivity claims (Novartis patents through 2032) and biosimilar status.
Label does not address patents or biosimilar status.
No generics or biosimilars are approved yet.
Label does not address generic/biosimilar status.
Patent 10,577,415 covers the formulation and method of use.
Label does not reference this patent number.
Contradictions
Low
AI Statement
In ASCLEPIOS I/II trials, Kesimpta cut annualized relapse rates by 51% versus Aubagio.
Label Reference
Section 14
Important Omissions
Boxed warning status for PML is not explicitly captured in the claims; label indicates PML risk.
Importance:
Moderate
Storage and handling details (refrigeration, room temperature times, single-use) are not fully captured in the claims.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
Label lists common adverse reactions (infections, injection-related reactions, headache) with generally manageable risk; rare but serious risks include PML and HBV reactivation. Monitoring and pre-treatment screening mitigate risk.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Several claims are not supported by the label or contradict label content; some assertions are not label-supported (regional approvals, manufacturer, patent status, onset timing).
Suggested Improvement
Limit claims to label-supported content; avoid asserting regulatory or patent details not present in the label; ensure trial results are accurately represented against the approved comparator and not misattributed to non-labeled comparators.